Acuitive Technologies

Acuitive Technologies is an orthopedic medical device company leveraging its proprietary CITREGEN® biomaterial platform to develop a portfolio of regenerative and fixation devices. The company focuses on addressing clinical shortcomings in current orthopedic devices, particularly in soft tissue repair and bone grafting, with products designed to enhance healing. Led by a seasoned team with decades of orthopedic industry experience, Acuitive is positioned to compete in the large and growing sports medicine and orthopedic reconstruction markets. Its strategy combines bioactive material science with practical surgical device design.

CITREGEN®: A synthetic biomaterial platform based on citrate, a natural metabolic molecule. It is engineered to resorb via hydrolysis, releasing citrate, calcium, and phosphate to create a local metabolic environment that guides and enhances tissue regeneration for bone and soft tissue repair.

Acuitive competes in the crowded orthopedic devices market against giants like Stryker, Johnson & Johnson (DePuy Synthes), Zimmer Biomet, and Smith & Nephew, as well as specialized sports medicine companies like Arthrex. Its primary differentiation is the bioactive, metabolic action of its CITREGEN platform, competing against traditional inert polymers, metal alloys, and passive calcium-based or demineralized bone matrix grafts.